We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 29. | 장 마감 후 (AMC) | $1 | — | — | $2.66B | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.16 | — | — | $2.26B | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.38 | — | — | $7.07B |
Consensus PT $7.5 · 6 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 04. 28. | RBC Capital | — | 의견 유지 | Sector Perform → Sector Perform | — | RBC Capital: Sector Perform |
| 2026. 02. 26. | Barclays | — | 의견 유지 | Equal-Weight → Equal-Weight | — | Barclays: Equal-Weight |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.15 | — | — | $4.56B | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Stored first · Google News · Yahoo Finance (English)
Bausch (BHC) Down 5.4% Since Last Earnings Report: Can It Rebound?
Bausch Health Companies stock (CA0717341071): China Thermage trademark adds to valuation debate - AD HOC NEWS
Bausch Health Companies stock (CA0717341071): China Thermage trademark adds to valuation debate AD HOC NEWS
Bausch Health, Solta Medical Say Thermage Brand Receives China Trademark Certification
Bausch Health Companies stock (CA0717341071): shares steady around 5.58 USD as investors watch pharm - AD HOC NEWS
Bausch Health Companies stock (CA0717341071): shares steady around 5.58 USD as investors watch pharm AD HOC NEWS
Oligometastatic Disease Market Analysis Report 2026-2036, Profiles of Leading Players - Dompe Farmaceutici, Bausch Health, Merck, Pfizer, and Glenmark Pharmaceuticals
Bausch Health Announces 2026 Annual Meeting of Shareholder Results